CERE240517P45000
- 3.50
- 0.000.00%
Cerevel Therapeutics Holdings Newsroom
Cerevel Therapeutics Holdings(CERE.US) Director Sells US$2.11 Million in Common Stock
$Cerevel Therapeutics Holdings(CERE.US)$ Director COLES N ANTHONY sold 50,000 shares of common stock on May 10, 2024 at an average price of $42.1025 for a total value of $2.11 million.Source: Announce
Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,105,125, According to a Recent SEC Filing
N Anthony Coles, Director, on May 10, 2024, sold 50,000 shares in Cerevel Therapeutics Holdings (CERE) for $2,105,125. Following the Form 4 filing with the SEC, Coles has control over a total of 15,63
Form 144 | Cerevel Therapeutics Holdings(CERE.US) Director Proposes to Sell 2.12 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 10, $Cerevel Therapeutics Holdings(CERE.US)$ Director NEAVELLE ANTHONY COLES intends to sell 50,000 shares of its common stock on May 10, with a total market value of appro
Cerevel Therapeutics Holdings | 10-Q: Quarterly report
Cerevel Therapeutics Holdings Insiders Placed Bullish Bets Worth US$2.51m
Quite a few insiders have dramatically grown their holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) over the past 12 months. An insider's optimism about the company's prospects is a posit
Cerevel (CERE.US), acquired by ABBV.US (ABBV.US), achieves key targets for advanced Parkinson's disease drugs
Cerevel Therapeutics announced Thursday that its once-a-day oral drug candidate for Parkinson's disease, tavapadon, has achieved key goals in a key phase 3 trial as a combination therapy.
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
Health care stocks were mixed pre-bell Thursday, with the iShares Biotechnology ETF (IBB) down 0.1% and the Health Care Select Sector SPDR Fund (XLV) 0.4% higher. Elevance Health (ELV) stock was up mo
AbbVie Buyout Cerevel Posts Late-stage Win for Parkinson's Disease Drug
Express News | Cerevel Therapeutics' Topline Results From Phase 3 TEMPO-3 Trial For Tavapadon For Parkinson's Disease, Met Primary Endpoint, Demonstrating Statistically Significant Increase In Total "On" Time Without Troublesome Dyskinesia Vs. Placebo
Express News | Cerevel Therapeutics Holdings Inc - Tavapadon Was Generally Well Tolerated
Express News | Cerevel: Statistically Significant Reduction in "off" Time, Key Secondary Endpoint, Observed for Tavapadon Treatment Arm
Express News | Cerevel Therapeutics Holdings Inc - Results From Tavapadon Phase 3 Monotherapy Trials (Tempo-1 and Tempo-2) Are Expected in Second Half of 2024
Express News | Cerevel Therapeutics Holdings Inc: Tavapadon Met Primary Endpoint in Pivotal Phase 3 Tempo-3 Adjunctive Trial
Express News | Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living With Parkinson’s Disease
AbbVie Slips After Revising Guidance to Reflect Earnings Impact
Cerevel Therapeutics Holdings(CERE.US) Director Sells US$2.12 Million in Common Stock
$Cerevel Therapeutics Holdings(CERE.US)$ Director COLES N ANTHONY sold 50,000 shares of Common Stock on Apr 1, 2024 at an average price of $42.3328 for a total value of $2.12 million.Source: Announcem
Form 144 | Cerevel Therapeutics Holdings(CERE.US) Director Proposes to Sell 2.11 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 1, $Cerevel Therapeutics Holdings(CERE.US)$ Director NEAVELLE ANTHONY COLES intends to sell 50,000 shares of its common stock on Apr 1, with a total market value of approxi
Cerevel Therapeutics Holdings(CERE.US) Director Sells US$2.05 Million in Common Stocks
$Cerevel Therapeutics Holdings(CERE.US)$ Director COLES N ANTHONY sold 50,000 shares of Common Stocks on Mar 4, 2024 at an average price of $41.011 for a total value of $2.05 million.Source: Announcem
Cerevel Therapeutics Holdings(CERE.US) Director Sells US$2.06 Million in Common Stocks
$Cerevel Therapeutics Holdings(CERE.US)$ Director COLES N ANTHONY sold 50,000 shares of Common Stocks on Feb 29, 2024 at an average price of $41.1578 for a total value of $2.06 million.Source: Announc
Market Chatter: AbbVie Plans $13 Billion Bond Sale to Fund Acquisitions
AbbVie (ABBV) is planning a $13 billion corporate bond sale to finance acquisitions of ImmunoGen and Cerevel Therapeutics Holdings (CERE), Bloomberg News reported, citing people with knowledge of the